secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2024-02-12T23:59:59+00:00
Accession:  0001516551-24-000008
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience raises $46.2M, sells real estate; equity now $49M for Nasdaq compliance
--------------------------------------------------------------------------------

- Net proceeds of ~$46.2M from private placement of 11.7M shares and pre-funded warrants on Jan 31, 2024.
- Subsidiary Avalite Sciences sold real estate on Jan 19, 2024, contributing ~$1.14M gain to equity.
- Pro forma stockholders' equity as of Sept 30, 2023 adjusted to $49.05M from $1.70M.
- Company believes equity now exceeds $5M minimum required for initial listing on The Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655124000008/0001516551-24-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655124000008/skye-20240212.htm
  HTML page:      https://secwatch.observer/filing/0001516551-24-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer